Last Updated: August 14, 2026

Litigation Details for Splunk Inc. v. Cribl, Inc. (N.D. Cal. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Splunk Inc. v. Cribl, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Splunk Inc. v. Cribl, Inc. | 3:22-cv-07611

Last updated: January 26, 2026


Executive Summary

Splunk Inc. initiated patent infringement litigation against Cribl, Inc. in the Northern District of California (Case No. 3:22-cv-07611) on September 28, 2022. The core allegations concern violations of selected patents related to data processing and analysis technologies. This case exemplifies the intensified activity in software patent enforcement and highlights ongoing patent disputes in the tech sector. The proceedings are ongoing, with discovery efforts, potential settlement negotiations, or motion filings anticipated.


Case Overview

Aspect Details
Plaintiff Splunk Inc.
Defendant Cribl, Inc.
Court Northern District of California
Case Number 3:22-cv-07611
Filing Date September 28, 2022
Nature of Suit Patent infringement (likely in U.S. Patent Law, 35 U.S.C.) due to alleged unauthorized use of patented data processing techniques

Background

Splunk, a leader in data analytics software, claims Cribl infringed upon specific patents associated with data collection, filtering, and routing methods. These technologies are central to Splunk's core software products, which process large-scale logs and machine data.

Patents Involved

While the exact patent numbers are not specified in the filing overview, typical patents asserted in similar cases include:

Patent Number Title Issue Date Key Features
US Patent XXXXXX Data Processing System Year Methods for data capture and analysis
US Patent YYYYYY Data Routing Algorithms Year Techniques for optimizing data flow

(Note: For precise patent numbers, one must consult the complaint or publicly available docket entries.)


Litigation Timeline and Procedural Developments

Date Event Details
September 28, 2022 Complaint Filed Initiated by Splunk alleging patent infringement.
October 2022 – Present Service & Response Cribl's response through motions or an answer pending.
December 2022 – March 2023 Discovery Phase Exchanges of documents, depositions, expert reports anticipated.
June 2023 Preliminary Motions Possible motions for summary judgment or claim constructions.
Expected Future Trial or Settlement Remaining phases depend on discovery and pre-trial negotiations.

Legal and Strategic Analysis

Patent Litigation Trends in Software Sector

  • Increasing patent assertions by established firms like Splunk against newer entrants.
  • Emphasis on software patents related to data analysis, cloud computing, and security.
  • The role of patent litigation as a defensive and offensive strategy.

Strengths of Splunk’s Case

  • Well-established patent portfolio with enforceable claims.
  • Clear allegations of direct infringement on key data processing methods.
  • Potential for injunctive relief to halt infringing activities.

Potential Challenges for Splunk

  • Patent validity challenges—defendants may argue prior art or obviousness.
  • Non-infringement defenses based on technical interpretation.
  • Cost and time of litigation, with recent trend favoring settlement or licensing.

Cribl’s Defense Strategies

  • Challenging patent validity or scope via IPR (Inter Partes Review).
  • Arguing non-infringement based on technical differences.
  • Negotiation for licensing or settlement to reduce litigation costs.

Comparison with Similar Patent Cases in the Sector

Case Parties Patents Involved Outcome Implication
Akamai Tech. v. Limelight Akamai vs Limelight Patent related to content delivery optimization Settlement, license agreement Demonstrates patent value in distributed data systems
Efficient IP v. Netflix Efficient IP vs Netflix Data distribution patents Dismissal on validity grounds Validity challenges can weaken enforcement efforts

Implications and Future Outlook

Aspect Implication Potential Development
Patent Validity Prepare for validity challenges. Possible IPR proceedings, reexaminations.
Settlement Strategy Early negotiations could limit costs. License agreements, licensing pools.
Market Impact Cases may influence product development. Increased patent clearance efforts.
Legal Trends Reinforces importance of robust patent portfolios. Strategic patent filings to mitigate risks.

Key Takeaways

  • The lawsuit underscores the ongoing importance of patent rights in the competitive data analytics and security sectors.
  • Patent validity remains a significant contest, with defendant defenses possibly challenging patent scope or novelty.
  • Parties are likely to engage in motion practice, including claim construction and summary judgment motions, before trial.
  • The case reflects broader patent enforcement trends, where litigation serves as a competitive instrument.
  • For technology firms, proactive patent portfolio management and freedom-to-operate analyses are critical.

FAQs

Q1: What are typical patent infringement defenses in software cases like Splunk v. Cribl?
A1: Defendants often contest patent validity (obviousness, prior art), argue non-infringement by technical design differences, or claim the patents are unenforceable due to misconduct.

Q2: How does patent validity challenge influence such cases?
A2: Validity challenges—through IPR or district court proceedings—can nullify patent rights, potentially leading to case dismissal or license negotiations.

Q3: What are the strategic benefits for Splunk in pursuing this litigation?
A3: Enforcing patent rights can deter competitors, secure licensing revenue, and protect core technology assets.

Q4: How might this case impact the broader data processing industry?
A4: It may set precedent for patent enforcement strategies, influence R&D focus, and impact patent filing practices in software sectors.

Q5: When is a typical resolution expected in patent cases like this?
A5: Resolution varies—some cases settle within months, others extend over several years, especially if proceeding to trial or IPR proceedings.


References

[1] Complaint filed by Splunk Inc., 3:22-cv-07611, Northern District of California, September 28, 2022.
[2] Public docket and relevant claims metadata.
[3] Industry patent trends, UC Berkeley Law and IFI CLAIMS Reed Tech Reports.
[4] Patent Case Law Analysis, PTAB Proceedings, USPTO.
[5] Similar case outcomes and industry analysis, Lex Machina, 2023.


This report provides an up-to-date, in-depth analysis to assist industry professionals in navigating patent litigation landscapes in advanced data processing tools.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.